Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly d...

Descripción completa

Detalles Bibliográficos

Autores principales:	Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Gunjan L. Shah, Michael Scordo, Sergio A. Giralt, Alexander Lesokhin, Saad Z. Usmani, Ola Landgren, Neha Korde
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Publishing Group 2023-07-01
Colección:	Blood Cancer Journal
Acceso en línea:	https://doi.org/10.1038/s41408-023-00882-y
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!